Gilead Sciences, Inc.

Symbol: GILD

NASDAQ

64.58

USD

Market price today

  • 166.3869

    P/E Ratio

  • 0.5630

    PEG Ratio

  • 80.53B

    MRK Cap

  • 0.05%

    DIV Yield

Gilead Sciences, Inc. (GILD) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.78%

Operating Profit Margin

0.34%

Net Profit Margin

0.02%

Return on Assets

0.01%

Return on Equity

0.02%

Return on Capital Employed

0.21%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO:Mr. Daniel P. O'Day
Full-time employees:18000
City:Foster City
Address:333 Lakeside Drive
IPO:1992-01-22
CIK:0000882095

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

General Outlook

When we look at how much money they make before expenses, they keep 0.777% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.336%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.018%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.009% return, is a testament to Gilead Sciences, Inc.'s adeptness in optimizing resource deployment. Gilead Sciences, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.023%. Furthermore, the proficiency of Gilead Sciences, Inc. in capital utilization is underscored by a remarkable 0.213% return on capital employed.

Stock Prices

Gilead Sciences, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $65.89, while its low point bottomed out at $64.97. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Gilead Sciences, Inc.'s stock market.

Liquidity Ratios

Analyzing GILD liquidity ratios reveals its financial health of the firm. The current ratio of 97.96% gauges short-term asset coverage for liabilities. The quick ratio (108.37%) assesses immediate liquidity, while the cash ratio (36.25%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio97.96%
Quick Ratio108.37%
Cash Ratio36.25%

Profitability Ratios

GILD profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 3.91% underscores its earnings before tax deductions. The effective tax rate stands at 57.41%, revealing its tax efficiency. The net income per EBT, 45.11%, and the EBT per EBIT, 11.63%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 33.62%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin3.91%
Effective Tax Rate57.41%
Net Income per EBT45.11%
EBT per EBIT11.63%
EBIT per Revenue33.62%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.98, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding108
Days of Inventory Outstanding201
Operating Cycle262.69
Cash Conversion Cycle263
Receivables Turnover5.88
Inventory Turnover1.82
Fixed Asset Turnover5.16
Asset Turnover0.49

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 6.80, and free cash flow per share, 6.34, depict cash generation on a per-share basis. The cash per share value, 7.57, showcases liquidity position. A payout ratio of 7.91 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.31, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share6.80
Free Cash Flow per Share6.34
Cash per Share7.57
Payout Ratio7.91
Operating Cash Flow Sales Ratio0.31
Free Cash Flow to Operating Cash Flow Ratio0.93
Cash Flow Coverage Ratio0.33
Capital Expenditure Coverage Ratio14.60
Dividend Paid and Capex Coverage Ratio1.92
Dividend Payout Ratio0.04

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 45.87%, highlights its total liabilities relative to assets. With a debt-equity ratio of 1.48, we discern the balance between debt and equity financing. The long-term debt to capitalization, 59.67%, and total debt to capitalization, 59.67%, ratios shed light on its capital structure. An interest coverage of 9.53 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio45.87%
Debt Equity Ratio1.48
Long Term Debt to Capitalization59.67%
Total Debt to Capitalization59.67%
Interest Coverage9.53
Cash Flow to Debt Ratio0.33
Company Equity Multiplier3.22

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 21.73, provides a glimpse into top-line earnings distributed across each share. Net income per share, 4.54, reflects the portion of profit attributed to each share. The book value per share, 18.23, represents the net asset value distributed per share, while the tangible book value per share, -9.63, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share21.73
Net Income Per Share4.54
Book Value Per Share18.23
Tangible Book Value Per Share-9.63
Shareholders Equity Per Share18.23
Interest Debt Per Share20.78
Capex Per Share-0.47

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -0.60%, indicates top-line expansion, while the gross profit growth, -2.20%, reveals profitability trends. EBIT growth, 27.80%, and operating income growth, 27.80%, offer insights into operational profitability progression. The net income growth, 23.37%, showcases bottom-line expansion, and the EPS growth, 24.04%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-0.60%
Gross Profit Growth-2.20%
EBIT Growth27.80%
Operating Income Growth27.80%
Net Income Growth23.37%
EPS Growth24.04%
EPS Diluted Growth23.63%
Weighted Average Shares Growth-0.56%
Weighted Average Shares Diluted Growth-0.32%
Dividends per Share Growth3.27%
Operating Cash Flow Growth-11.75%
Free Cash Flow Growth-11.06%
10-Year Revenue Growth per Share196.50%
5-Year Revenue Growth per Share27.46%
3-Year Revenue Growth per Share10.62%
10-Year Operating CF Growth per Share215.82%
5-Year Operating CF Growth per Share-0.87%
3-Year Operating CF Growth per Share-1.28%
10-Year Net Income Growth per Share125.67%
5-Year Net Income Growth per Share8.01%
3-Year Net Income Growth per Share6311.07%
10-Year Shareholders Equity Growth per Share137.25%
5-Year Shareholders Equity Growth per Share9.87%
3-Year Shareholders Equity Growth per Share25.75%
5-Year Dividend per Share Growth per Share33.34%
3-Year Dividend per Share Growth per Share11.23%
Receivables Growth-2.45%
Inventory Growth19.36%
Asset Growth-1.66%
Book Value per Share Growth7.86%
Debt Growth-0.96%
R&D Expense Growth14.93%
SGA Expenses Growth6.82%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 120,002,480,000, captures the company's total value, considering both debt and equity. Income quality, 1.43, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.19, gauges operational efficiency, while the research and development to revenue, 21.09%, highlights investment in innovation. The ratio of intangibles to total assets, 55.96%, indicates the value of non-physical assets, and capex to operating cash flow, -7.31%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value120,002,480,000
Income Quality1.43
Sales General and Administrative to Revenue0.19
Research and Development to Revenue21.09%
Intangibles to Total Assets55.96%
Capex to Operating Cash Flow-7.31%
Capex to Revenue-2.16%
Capex to Depreciation-21.72%
Stock-Based Compensation to Revenue2.82%
Graham Number43.15
Return on Tangible Assets20.71%
Graham Net Net-21.58
Working Capital5,174,000,000
Tangible Asset Value-12,019,000,000
Net Current Asset Value-22,922,000,000
Invested Capital1
Average Receivables4,718,500,000
Average Payables727,500,000
Average Inventory3,093,000,000
Days Sales Outstanding63
Days Payables Outstanding34
Days of Inventory On Hand206
ROIC16.06%
ROE0.25%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 4.61, and the price to book ratio, 4.61, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.93, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 10.19, and price to operating cash flows, 9.50, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio4.61
Price to Book Ratio4.61
Price to Sales Ratio2.93
Price Cash Flow Ratio9.50
Price Earnings to Growth Ratio0.56
Enterprise Value Multiple5.43
Price Fair Value4.61
Price to Operating Cash Flow Ratio9.50
Price to Free Cash Flows Ratio10.19
Price to Tangible Book Ratio4.44
Enterprise Value to Sales4.43
Enterprise Value Over EBITDA10.26
EV to Operating Cash Flow14.99
Earnings Yield5.60%
Free Cash Flow Yield7.34%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Gilead Sciences, Inc. (GILD) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 166.387 in 2024.

What is the ticker symbol of Gilead Sciences, Inc. stock?

The ticker symbol of Gilead Sciences, Inc. stock is GILD.

What is company IPO date?

IPO date of Gilead Sciences, Inc. is 1992-01-22.

What is company current share price?

Current share price is 64.580 USD.

What is stock market cap today?

The market cap of stock today is 80529322600.000.

What is PEG ratio in 2024?

The current 0.563 is 0.563 in 2024.

What is the number of employees in 2024?

In 2024 the company has 18000.